US20090042821A1 - Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials - Google Patents

Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials Download PDF

Info

Publication number
US20090042821A1
US20090042821A1 US11/914,867 US91486706A US2009042821A1 US 20090042821 A1 US20090042821 A1 US 20090042821A1 US 91486706 A US91486706 A US 91486706A US 2009042821 A1 US2009042821 A1 US 2009042821A1
Authority
US
United States
Prior art keywords
dosage form
solid dosage
form according
excipients
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/914,867
Other languages
English (en)
Inventor
Arno Appavoo Enose
Harish Kumar Madan
Sumit Madan
Anupam Trehan
Puneet Tyagi
Vinod Kumar Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Assigned to RANBAXY LABORATORIES LIMITED reassignment RANBAXY LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TYAGI, PUNEET, ARORA, VINOD KUMAR, TREHAN, ANUPAM, ENOSE, ARNO APPAVOO, MADAN, HARISH KUMAR, MADAN, SUMIT
Publication of US20090042821A1 publication Critical patent/US20090042821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/02—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation.
  • Malaria the most common parasitic disease of humans, remains a major health and economic burden in most tropical countries. Large areas of Central and South America, Hispaniola (Haiti and the Dominican Republic), Africa, the Middle East, the Indian subcontinent, Southeast Asia, and Oceania are considered as malaria-risk areas. It leads to a heavy toll of illness and death especially amongst children and pregnant women. According to the World Health Organization, it is estimated that the disease infects about 400 million people each year, and around two to three million people die from malaria every year. There are four kinds of malaria parasites that infect human: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.
  • the clinical symptoms of malaria are generally associated with the bursting of red blood cells causing an intense fever associated with chills that can leave the infected individual exhausted and bedridden. More severe symptoms associated with repeat infections and/or infection by Plasmodium falciparum include anaemia, severe headaches, convulsions, delirium and, in some instances, death.
  • Quinine an antimalarial compound that is extracted from the bark of cinchona tree, is one of the oldest and most effective drugs in existence. Chloroquine and mefloquine are the synthetic analogs of quinine developed in 1940's, which due to their effectiveness, ease of manufacture, and general lack of side effects, became the drugs of choice. The downside to quinine and its derivatives is that they are short-acting and have bitter taste. Further, they fail to prevent disease relapses and are also associated with side effects commonly known as ‘Chinchonism syndrome’ characterized by nausea, vomiting, dizziness, vertigo and deafness. However, in recent years, with the emergence of drug-resistant strains of parasite and insecticide-resistant strains of vector, the treatment and/or control of malaria is becoming difficult with these conventional drugs.
  • trioxolane derivatives possess excellent potency, efficacy against Plasmodium parasites, and a lower degree of neurotoxicity, in addition to their structural simplicity and ease of synthesis. Furthermore, these compounds have half lives which are believed to permit short-term treatment regimens comparing favorably to other artemisinin-like drugs.
  • the therapeutic dose of trioxolane derivative may range between about 0.1-1000 mg/kg/day, in particular between about 1-100 mg/kg/day.
  • the foregoing dose may be administered as a single dose or may be divided into multiple doses.
  • a typical dosing schedule could be, for example, 2.0-1000 mg/kg weekly beginning 1-2 weeks prior to malaria exposure continued up to 1-2 weeks post-exposure.
  • trioxolanes there are certain limitations for formulators developing formulations with trioxolones, the first being their susceptibility to degradation in presence of moisture that results in reduced shelf lives. Another is their bitter taste, which can result in poor compliance of the regimen or selection of another, possibly less effective, therapeutic agent.
  • a stable antimalarial oral solid dosage form comprising Spiro or dispiro 1,2,4-trioxolanes can be prepared by controlling the water content below a certain critical limit. Further the bitter taste can be masked by applying a film coating layer to the solid dosage form.
  • a stable oral solid dosage form that includes a therapeutically effective amount of a compound having the structure of Formula I,
  • R 1 and R 2 are same or different and are selected from hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and substituted or unsubstituted alicyclic groups that are optionally interrupted by one or more oxygen, sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, and a halogen, and further providing that the spirocyclohexyl ring attaching R 1 and R 2 are optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms; and one or more pharmaceutically acceptable excipients, wherein not more than 5% w/w total related substances are formed on storage at 40 ⁇ 2° C. and 75 ⁇ 5% relative humidity over a period of 6 months.
  • Embodiments of the oral solid dosage form may include one or more of the following features.
  • the dosage form may include one or more of other antimalarial drugs.
  • the other antimalarial drugs may include quinine, mefloquine, lumefantrine, sulfadoxine-pyrimethamine, dihydroartimisinin, piperaquine, chloroquine, amodiaquine, proguanil, atovaquone, chloroproguanil, dapsone, fosmidomycin, tetracycline, DB 289 (pafuramidine maleate), clindamycin, their salts and derivatives thereof.
  • piperaquine, lumefantrine and DB 289 may be used.
  • the pharmaceutically acceptable excipients may include one or more of binders, diluents, glidants/lubricants, disintegrants, surfactants and coloring agents.
  • a stable oral solid dosage form of a therapeutically effective amount of a compound having the structure of Formula I which is formulated using a dry or non-aqueous process.
  • the solid dosage form may be in the form of a tablet and the tablet may be coated.
  • a process for the preparation of a stable oral solid dosage form includes blending a compound having the structure of Formula I and one or more intragranular excipients; granulating the blend to form granules; blending the granules with one or more extragranular excipients; and compressing the blend into tablet or filling into capsule.
  • Embodiments of the process may include one or more of the following features.
  • the granulation may be wet granulation and the wet granulation may include a non-aqueous granulating liquid selected from ethanol, isopropyl alcohol, acetone, dichloromethane, and a binder solution.
  • the granulation may be dry granulation and the dry granulation may be compaction or slugging.
  • the dry granulation may be compaction for example, dry roller compaction.
  • the tablet may be coated with one or more film coating layers.
  • a process for the preparation of a stable oral solid dosage form includes blending a compound having the structure of Formula I, and one or more pharmaceutically acceptable excipients; directly compressing the blend into tablet or filling into capsule; and optionally applying one or more film coating layers to the tablet.
  • a process for the preparation of a stable oral solid dosage form includes granulating a blend of one or more excipients; drying the excipient granules; blending excipient granules with a compound having the structure of Formula I, or with granules comprising a compound having the structure of Formula I; compressing the blend into tablet or filling into capsule; and optionally applying one or more film coating layers to the tablet.
  • Embodiments of the process may include one or more of the following features.
  • the granulation may be wet granulation and the wet granulation may include a granulating liquid selected from water, ethanol, isopropyl alcohol, acetone, dichloromethane, and a binder solution.
  • the granulation may be dry granulation and the dry granulation may be compaction or slugging.
  • the dry granulation may be compaction for example, dry roller compaction.
  • a method of prophylaxis or treatment of malaria includes administering a solid dosage form that includes a therapeutically effective amount of a compound having the structure of Formula I; and one or more pharmaceutically acceptable excipients, wherein not more than 5% w/w total related substances are formed on storage at 40 ⁇ 2° C. and 75 ⁇ 5% relative humidity over a period of 6 months.
  • Embodiments of the oral solid dosage form may include one or more of the following features.
  • the dosage form may include one or more other antimalarial drugs.
  • the other antimalarial drugs may include quinine, mefloquine, lumefantrine, sulfadoxine-pyrimethamine, dihydroartimisinin, piperaquine, chloroquine, amodiaquine, proguanil, atovaquone, chloroproguanil, dapsone, fosmidomycin, tetracycline, DB 289 (pafuramidine maleate), clindamycin, their salts and derivatives thereof.
  • piperaquine, lumefantrine and DB 289 may be used.
  • a method of prophylaxis or treatment of malaria includes administering a solid dosage form that includes a therapeutically effective amount of a compound having the structure of Formula I, which is formulated using a dry or non-aqueous process.
  • a stable oral solid dosage form includes a therapeutically effective amount of a compound having the structure of Formula I; at least one other antimalarial drug selected from lumefantrine, piperaquine, or DB 289; and one or more pharmaceutically acceptable excipients.
  • Embodiments of the oral dosage form may include one or more of the following features.
  • the water content of the dosage form may not be more than 6.5% w/w.
  • a stable oral solid dosage form includes cis-adamantane-2-spiro-3′-8′-[[[(2′-amino-2′-methylpropyl)amino]carbonyl]methyl] -1′,2′,4′-trioxaspiro[4.5]decane hydrogen maleate; piperaquine; and one or more pharmaceutically acceptable excipients.
  • stable refers to chemical stability of active compound in solid dosage forms against decomposition occurring during shelf life due to hydrolysis, wherein not more than 5% w/w total related substances are formed on storage at 40 ⁇ 2° C. and 75 ⁇ 5% relative humidity over a period of 6 months.
  • solid dosage form as used herein includes tablets or coated tablets, capsules, pellets, pills, granules, powders, and the like.
  • a particularly suitable solid dosage form is that of tablets.
  • the present invention provides stable oral solid dosage forms of active compound, by using excipients having low water content and manufactured using dry or non-aqueous formulation processes.
  • active compound as used herein includes spiro or dispiro 1,2,4-trioxolane compound of Formula I
  • R 1 and R 2 are same or different and are selected from hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and substituted or unsubstituted alicyclic groups that are optionally interrupted by one or more oxygen, sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, and a halogen, and further providing that the spirocyclohexyl ring attaching R 1 and R 2 are optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms.
  • R 1 is hydrogen, for example, compounds having the structure of Formula II.
  • Active compound includes one or more of the various spiro and dispiro trioxolane derivatives disclosed in U.S. Application No. 2004/0186168; U.S. Pat. Nos. 6,486,199 and 6,825,230 and are incorporated herein by reference. These trioxolanes are relatively sterically hindered on at least one side of the trioxolane heterocycle which provides better in vivo activity, especially with respect to oral administration. Particularly, spiro and dispiro 1,2,4-trioxolanes derivatives possess excellent potency and efficacy against Plasmodium parasites, and a lower degree of neurotoxicity.
  • Active compound includes free form of the compounds referred to herein as well as their pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, polymorphs, metabolites, prodrugs and analogues.
  • active compound is cis-adamantane-2-spiro-3′-8′-[[[(2′-amino-2′-methylpropyl)amino]carbonyl]methyl]-1′,2′,4′-trioxaspiro[4.5]decane hydrogen maleate.
  • the stable oral solid dosage forms of the present invention may further comprise one or more pharmaceutically acceptable excipients, which include all physiologically inert excipients used in the art for the preparation of solid dosage forms. Examples include binders, diluents, glidants/ lubricants disintegrants, surfactants, coloring agents, and the like.
  • the excipients may be used either intragranularly or extragranularly, or both.
  • the weight ratio of active compound and excipients in the dosage forms may vary from about 1.5:1 to about 1:30.
  • binder examples include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, agar, tragacanth, sodium alginate, and the like.
  • disintegrants include clays, celluloses, alginates, gums, cross-linked polymers (such as cross-linked polyvinylpyrrolidone and cross-linked sodium carboxymethylcellulose), sodium starch glycolate, low-substituted hydroxypropyl cellulose, soy polysaccharides, and the like.
  • lubricants or ‘glidants’ include talc, magnesium stearate, calcium stearate, stearic acid, colloidal silicon dioxide, magnesium carbonate, magnesium oxide, calcium silicate, microcrystalline cellulose, mineral oil, waxes, glyceryl behenate, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, sodium laurylsulfate, sodium stearyl fumarate, and hydrogenated vegetable oils, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and the like.
  • the ‘coloring agents’ include any FDA approved colors for oral use.
  • the solid dosage forms may further be coated with one or more functional and/or non-functional layers comprising film-forming polymers, and other coating additives.
  • film-forming polymers examples include cellulose derivatives such as ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, partially hydrolyzed polyvinyl alcohol, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate; waxes such as polyethylene glycol; methacrylic acid polymers such as Eudragit® RL and RS; and the like.
  • commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry® may also be used for coating.
  • the ‘coating additives’ include plasticizers, glidants or flow regulators, opacifiers and lubricants.
  • Solid dosage forms of active compound may be prepared by densifying active compound and one or more excipients, and processing into solid dosage forms. Densification may be carried out using any conventional method known in the art. In particular, granulation or extrusion-spheronization may be used.
  • stable oral tablet of active compound may be prepared by a process comprising the steps of blending active compound and intragranular portion of a diluent, lubricant, and disintegrant; passing the blend through a roller compactor to form a compact mass; reducing the compact into granules of suitable size; blending the granules with extragranular portion of a lubricant, disintegrant, and diluent in a double cone blender; and finally compressing into tablets using suitable tooling.
  • stable oral tablet of active compound may be prepared by a process comprising the steps of blending active compound, intragranular portion of a diluent, lubricant, and disintegrant; compressing the blend in a heavy tabletting press to form slugs; reducing the slugs into granules of suitable size; blending the granules with extragranular portion of a lubricant, disintegrant, and diluent in a double cone blender; and finally compressing into tablets using suitable tooling.
  • stable oral capsule of active compound may be prepared by a process comprising the steps of blending active compound, intragranular portion of a diluent, lubricant, and disintegrant; passing the blend through a roller compactor to form a compact mass; reducing the compact into granules of a suitable size; blending the granules with extragranular portion of a lubricant in a double cone blender; and finally filling into capsules of a suitable size.
  • stable oral capsule of active compound may be prepared by a process comprising the steps of blending active compound, intragranular portion of diluent, and disintegrant; wet granulating the blend with a non aqueous granulating fluid or a solution/dispersion of pharmaceutically acceptable excipients in the non-aqueous granulating fluid; drying and reducing the granules to a suitable size, blending the granules with extragranular portion of lubricant, in a double cone blender; and finally filling into capsules of a suitable size.
  • Active compound and intragranular portion of microcrystalline cellulose were sieved through sieve BSS# 44 and mixed together in a double cone blender to form a uniform blend.
  • step 3 The blend of step 2 was compacted in a roller compactor and was sifted through sieve BSS # 22 to form granules.
  • Example 2 The tablets prepared as per Example 1 were subjected to stability studies at 25° C./RH 60%, 30° C./RH 65% and 40° C./RH 75% over a period of 6 months. The results are summarized in Table 2. The results of in vitro drug release analyzed at predetermined time periods are given in Table 3.
  • the tablets prepared by the process of the present invention in which water is absent shows acceptable shelf stability.
  • Active compound, microcrystalline cellulose, croscarmellose sodium and magnesium stearate were sifted through sieve BSS# 44.
  • step 3 To the blend of step 2, sifted magnesium stearate was added and mixed for about 5 minutes.
  • step 3 The blend obtained in step 3 was directly compressed using suitable size capsule shape punches to obtain compressed tablets.
  • Example 3 % w/w
  • Example 4 % w/w Intragranular Maleate salt of a compound of 7.68 13.8 Formula II (active compound) Piperquine phosphate 61.80 55.5 Microcrystalline Cellulose 20.39 21.05 Magnesium stearate 0.44 0.39 Crospovidone 2.21 1.99 Extragranular Microcrystalline Cellulose 4.42 3.99 Crospovidone 2.21 1.99 Magnesium stearate 1.05 1.09 Coating Opadry ® O2B53782 orange 2.5 2.5 Water q.s q.s Total weight (mg) 1332.5 738 Water content ⁇ 6.55% w/w ⁇ 6.55% w/w/w
  • Active compound, piperaquine phosphate and intragranular portion of microcrystalline cellulose and crospovidone were sieved through sieve BSS # 44 and mixed together in a double cone blender to form a uniform blend.
  • step 2 To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes.
  • step 3 The blend of step 2 was compacted in a roller compactor and was sifted through sieve BSS # 18 to form granules.
  • step 5 The blend of step 5 was compressed using suitable size punches to obtain compressed tablets.
  • step 6 The tablets as obtained from step 6 were coated with Opadry® using conventional coating techniques and weight built of up to 2.5% w/w.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US11/914,867 2005-05-18 2006-05-18 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials Abandoned US20090042821A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1279/DEL/2005 2005-05-18
IN1279DE2005 2005-05-18
IN1192DE2006 2006-05-12
IN1192/DEL/2006 2006-05-12
PCT/IB2006/051588 WO2006123314A2 (en) 2005-05-18 2006-05-18 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/051588 A-371-Of-International WO2006123314A2 (en) 2005-05-18 2006-05-18 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/183,119 Continuation-In-Part US8664265B2 (en) 2005-05-18 2011-07-14 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Publications (1)

Publication Number Publication Date
US20090042821A1 true US20090042821A1 (en) 2009-02-12

Family

ID=37198895

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/914,867 Abandoned US20090042821A1 (en) 2005-05-18 2006-05-18 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
US13/183,119 Active US8664265B2 (en) 2005-05-18 2011-07-14 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/183,119 Active US8664265B2 (en) 2005-05-18 2011-07-14 Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Country Status (9)

Country Link
US (2) US20090042821A1 (zh)
EP (1) EP1898901B1 (zh)
CN (1) CN101272777B (zh)
CY (1) CY1118583T1 (zh)
ES (1) ES2615458T3 (zh)
HU (1) HUE033191T2 (zh)
PL (1) PL1898901T3 (zh)
PT (1) PT1898901T (zh)
WO (1) WO2006123314A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011483A1 (en) * 2010-03-31 2013-01-10 Supernus Pharmaceuticals, Inc. Formulations of mazindol

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
AP2525A (en) * 2006-05-17 2012-12-05 Ranbaxy Lab Ltd Antimarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative
CN103930107A (zh) * 2011-07-14 2014-07-16 兰贝克赛实验室有限公司 青蒿氧烷和哌喹的稳定剂型
WO2014132226A1 (en) * 2013-02-28 2014-09-04 Ranbaxy Laboratories Limited Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
US20140322296A1 (en) * 2013-03-22 2014-10-30 Aptalis Pharma S.R.L. Piperaquine microcapsules and compositions containing them
WO2015140709A1 (en) * 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
CN109464442B (zh) * 2018-11-19 2020-02-28 裴建梅 一种沙库巴曲缬沙坦钠药物组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US20040039008A1 (en) * 2002-06-21 2004-02-26 Medicines For Malaria Ventures Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US20040186168A1 (en) * 2002-06-21 2004-09-23 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US20040039008A1 (en) * 2002-06-21 2004-02-26 Medicines For Malaria Ventures Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US20040186168A1 (en) * 2002-06-21 2004-09-23 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011483A1 (en) * 2010-03-31 2013-01-10 Supernus Pharmaceuticals, Inc. Formulations of mazindol

Also Published As

Publication number Publication date
ES2615458T3 (es) 2017-06-07
EP1898901A2 (en) 2008-03-19
PL1898901T3 (pl) 2017-07-31
US20120183607A1 (en) 2012-07-19
EP1898901B1 (en) 2016-11-23
WO2006123314A2 (en) 2006-11-23
US8664265B2 (en) 2014-03-04
CN101272777B (zh) 2013-01-30
HUE033191T2 (en) 2017-11-28
WO2006123314A3 (en) 2008-04-10
CY1118583T1 (el) 2017-07-12
CN101272777A (zh) 2008-09-24
PT1898901T (pt) 2017-02-27

Similar Documents

Publication Publication Date Title
US8664265B2 (en) Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
RU2328274C2 (ru) Препарат ламотриджин с контролируемым высвобождением
HU186078B (en) Process for producing pharmaceutical compositions for peroral application containing dipyridamol
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
KR102072546B1 (ko) 레날리도마이드의 경구용 정제 조성물
JPH11501951A (ja) プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形
US5814339A (en) Film coated tablet of paracetamol and domperidone
KR101828630B1 (ko) 구강 내 붕괴 정제
AU2012282077A1 (en) Stable dosage forms of arterolane and piperaquine
KR20060010774A (ko) 판토프라졸을 활성 성분으로서 함유하는 제형
WO2010023690A2 (en) Prolonged release formulation of amisulpride
EP2368543A1 (en) Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
KR20140081826A (ko) 서방성 제제
EP3241549A1 (en) Sprinkle composition of cinacalcet
MX2014007635A (es) Composicion farmaceutica no enterica que comprende crofelemer.
US20210220373A1 (en) Orally disintegrating pharmacutical composition comprising nefopam and process for preparing the same
OA16845A (en) Stable dosage forms of arterolane and piperaquine
WO2014132226A1 (en) Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof
KR20190129880A (ko) 날푸라핀을 함유하는 정제화된 의약 조성물
KR20150045446A (ko) 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
KR20190064208A (ko) 피마살탄을 포함하는 고체 분산체
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2022074681A1 (en) Pharmaceutical compositions with enhanced blend uniformity and content uniformity
EP2698151A1 (en) Orally Disintegrating Formulation of Paliperidone
KR100212960B1 (ko) 경구용 복합제제

Legal Events

Date Code Title Description
AS Assignment

Owner name: RANBAXY LABORATORIES LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ENOSE, ARNO APPAVOO;MADAN, HARISH KUMAR;MADAN, SUMIT;AND OTHERS;REEL/FRAME:021207/0159;SIGNING DATES FROM 20071121 TO 20071123

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION